Literature DB >> 14986246

Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.

Robert Gaynes1, David Rimland, Edna Killum, H Ken Lowery, Theodore M Johnson, George Killgore, Fred C Tenover.   

Abstract

To determine the cause of an increase in the rate of Clostridium difficile-associated diarrhea (CDAD) in a long-term care facility (LTCF), we analyzed CDAD cases among LTCF patients from October 2001 through June 2002. CDAD cases were identified from review of all enzyme immunoassays positive for C. difficile toxin A. The increase coincided with a formulary change from levofloxacin to gatifloxacin. We performed a case-control study in which we randomly selected control subjects from 612 LTCF admissions during this period. Although we examined a variety of risk factors, logistic regression analysis only demonstrated associations between CDAD and use of clindamycin (P=.005) and gatifloxacin, the latter being associated with an increasing risk of CDAD with increasing duration of gatifloxacin therapy (P<.0001). We concluded that an outbreak of CDAD in an LTCF was associated with a formulary change from levofloxacin to gatifloxacin. The rate of CDAD in the LTCF decreased after a change back to levofloxacin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14986246     DOI: 10.1086/381551

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  57 in total

1.  Clostridium difficile infection in hospitals: risk factors and responses.

Authors:  Thomas J Louie; Jon Meddings
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

2.  In vivo selection of moxifloxacin-resistant Clostridium difficile.

Authors:  Ana Mena; Elena Riera; Carla López-Causapé; Irene Weber; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

3.  Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?

Authors:  Irfan A Dhalla; Muhammad M Mamdani; Andrew E Simor; Alex Kopp; Paula A Rochon; David N Juurlink
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.

Authors:  Nicole J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 5.  Review: Clostridium difficile-associated disorders/diarrhea and Clostridium difficile colitis: the emergence of a more virulent era.

Authors:  Perry Hookman; Jamie S Barkin
Journal:  Dig Dis Sci       Date:  2007-02-16       Impact factor: 3.199

6.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

7.  Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Authors:  Thomas Akerlund; Ingela Persson; Magnus Unemo; Torbjörn Norén; Bo Svenungsson; Marlene Wullt; Lars G Burman
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

Review 8.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

Review 10.  A review of the economics of treating Clostridium difficile infection.

Authors:  Kari A Mergenhagen; Amy L Wojciechowski; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.